An IL-5 Single-Nucleotide Polymorphism Influences Neuroinflammation and Prospective Disease Activity in Multiple Sclerosis
Abstract
:1. Introduction
2. Results
2.1. Clinical and Demographic Characteristics of Study Population
2.2. CSF Cytokine Levels Are Different in RR-MS, P-MS and Inflammatory Controls
2.3. rs2069812IL-5 SNP Is Associated with Prospective Disease Activity in MS
2.4. rs2069812 IL-5 SNP Influences Neuroinflammation in MS
3. Discussion
4. Materials and Methods
4.1. Patients
4.2. SNP IL-5 rs2069812 Analysis
4.3. CSF Collection and Analysis
4.4. MRI
4.5. Statistical Analysis
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
References
- Thompson, A.J.; Baranzini, S.E.; Geurts, J.; Hemmer, B.; Ciccarelli, O. Multiple sclerosis. Lancet 2018, 391, 1622–1636. [Google Scholar] [CrossRef]
- Compston, A.; Coles, A. Multiple sclerosis. Lancet 2008, 372, 1502–1517. [Google Scholar] [CrossRef] [PubMed]
- Tavakolpour, S. Interleukin 7 receptor polymorphisms and the risk of multiple sclerosis: A meta-analysis. Mult. Scler. Relat. Disord. 2016, 8, 66–73. [Google Scholar] [CrossRef] [PubMed]
- Ramakrishnan, V.; Husain, R.A.; Ahmed, S.S. Genetic predisposition of IL-10 promoter polymorphisms with risk of multiple sclerosis: A meta-analysis. J. Neuroimmunol. 2017, 306, 11–18. [Google Scholar] [CrossRef]
- Rossi, S.; Motta, C.; Studer, V.; Barbieri, F.; Buttari, F.; Bergami, A.; Sancesario, G.; Bernardini, S.; De Angelis, G.; Martino, G.; et al. Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult. Scler. J. 2014, 20, 304–312. [Google Scholar] [CrossRef]
- Rossi, S.; Studer, V.; Motta, C.; Germani, G.; Macchiarulo, G.; Buttari, F.; Mancino, R.; Castelli, M.; De Chiara, V.; Weiss, S.; et al. Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis. J. Neuroinflamm. 2014, 11, 32. [Google Scholar] [CrossRef] [PubMed]
- Bruno, A.; Dolcetti, E.; Azzolini, F.; Moscatelli, A.; Gambardella, S.; Ferese, R.; Rizzo, F.R.; Gilio, L.; Iezzi, E.; Galifi, G.; et al. Interleukin 6 SNP rs1818879 Regulates Radiological and Inflammatory Activity in Multiple Sclerosis. Genes 2022, 13, 897. [Google Scholar] [CrossRef]
- Dolcetti, E.; Bruno, A.; Azzolini, F.; Gilio, L.; Pavone, L.; Iezzi, E.; Galifi, G.; Gambardella, S.; Ferese, R.; Buttari, F.; et al. Genetic regulation of IL-8 influences disease presentation of multiple sclerosis. Mult. Scler. J. 2023, 29, 512–520. [Google Scholar] [CrossRef]
- Charlon, T.; Martínez-Bueno, M.; Bossini-Castillo, L.; Carmona, F.D.; Di Cara, A.; Wojcik, J.; Voloshynovskiy, S.; Martín, J.; Alarcón-Riquelme, M.E. Single Nucleotide Polymorphism Clustering in Systemic Autoimmune Diseases. PLoS ONE 2016, 11, e0160270. [Google Scholar] [CrossRef]
- Farh, K.K.H.; Marson, A.; Zhu, J.; Kleinewietfeld, M.; Housley, W.J.; Beik, S.; Shoresh, N.; Whitton, H.; Ryan, R.J.; Shishkin, A.A.; et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 2015, 518, 337–343. [Google Scholar] [CrossRef]
- Fidancı, İ.D.; Zülfikar, B.; Kavaklı, K.; Ar, M.C.; Kılınç, Y.; Başlar, Z.; Çağlayan, S.H. A Polymorphism in the IL-5 Gene is Associated with Inhibitor Development in Severe Hemophilia A Patients. Turk. J. Hematol. 2014, 31, 17–24. [Google Scholar] [CrossRef] [PubMed]
- Sawcer, S.; Hellenthal, G.; Pirinen, M.; Spencer, C.C.; Patsopoulos, N.A.; Moutsianas, L.; Dilthey, A.; Su, Z.; Freeman, C.; Hunt, S.E.; et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476, 214–219. [Google Scholar] [CrossRef] [PubMed]
- Rothenberg, M.E.; Hogan, S.P. The eosinophil. Annu. Rev. Immunol. 2006, 24, 147–174. [Google Scholar] [CrossRef]
- Maxeiner, H.-G.; Schneider, E.M.; Kurfiss, S.-T.; Brettschneider, J.; Tumani, H.; Bechter, K. Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases. Cytokine 2014, 69, 62–67. [Google Scholar] [CrossRef]
- Koper-Lenkiewicz, O.M.; Sutkowska, K.; Wawrusiewicz-Kurylonek, N.; Kowalewska, E.; Matowicka-Karna, J. Proinflammatory Cytokines (IL-1, -6, -8, -15, -17, -18, -23, TNF-α) Single Nucleotide Polymorphisms in Rheumatoid Arthritis—A Literature Review. Int. J. Mol. Sci. 2022, 23, 2106. [Google Scholar] [CrossRef]
- Tran, G.T.; Hodgkinson, S.J.; Carter, N.M.; Verma, N.D.; Plain, K.M.; Boyd, R.; Robinson, C.M.; Nomura, M.; Killingsworth, M.; Hall, B.M. IL-5 promotes induction of antigen-specific CD4+CD25+ T regulatory cells that suppress autoimmunity. Blood 2012, 119, 4441–4450. [Google Scholar] [CrossRef]
- Weir, C. IL-5-deficient mice are susceptible to experimental autoimmune encephalomyelitis. Int. Immunol. 2003, 15, 1283–1289. [Google Scholar] [CrossRef]
- Chen, Y.; Zheng, T.; Lan, Q.; Foss, F.; Kim, C.; Chen, X.; Dai, M.; Li, Y.; Holford, T.; Leaderer, B.; et al. Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood 2011, 117, 585–590. [Google Scholar] [CrossRef] [PubMed]
- Lan, Q. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006, 107, 4101–4108. [Google Scholar] [CrossRef]
- Mahajan, R.; El-Omar, E.M.; Lissowska, J.; Grillo, P.; Rabkin, C.S.; Baccarelli, A.; Yeager, M.; Sobin, L.H.; Zatonski, W.; Channock, S.J.; et al. Genetic Variants in T Helper Cell Type 1, 2 and 3 Pathways and Gastric Cancer Risk in a Polish Population. Jpn. J. Clin. Oncol. 2008, 38, 626–633. [Google Scholar] [CrossRef]
- Hsing, A.W.; Sakoda, L.C.; Rashid, A.; Andreotti, G.; Chen, J.; Wang, B.S.; Shen, M.C.; Chen, B.E.; Rosenberg, P.S.; Zhang, M.; et al. Variants in Inflammation Genes and the Risk of Biliary Tract Cancers and Stones: A Population-Based Study in China. Cancer Res. 2008, 68, 6442–6452. [Google Scholar] [CrossRef]
- Zhu, W.; Liu, N.; Zhao, Y.; Jia, H.; Cui, B.; Ning, G. Association analysis of polymorphisms in IL-3, IL-4, IL-5, IL-9, and IL-13 with Graves’ disease. J. Endocrinol. Investig. 2010, 33, 751–755. [Google Scholar] [CrossRef] [PubMed]
- Mestiri, S.; Zaaber, I.; Inoubli, O.; Abid, N.; Omrani, A.; Nejehi, H.; Marmouch, H. Association of cytokine Th2 gene polymorphisms with autoimmune thyroid diseases in Tunisian population. Int. J. Immunogenet. 2020, 47, 294–308. [Google Scholar] [CrossRef] [PubMed]
- Biały, S.; Iwaszko, M.; Świerkot, J.; Bugaj, B.; Kolossa, K.; Jeka, S.; Bogunia-Kubik, K. Th2 Cytokines (Interleukin-5 and -9) Polymorphism Affects the Response to Anti-TNF Treatment in Polish Patients with Ankylosing Spondylitis. Int. J. Mol. Sci. 2022, 23, 13177. [Google Scholar] [CrossRef]
- Parks, N.E.; Flanagan, E.P.; Lucchinetti, C.F.; Wingerchuk, D.M. NEDA treatment target? No evident disease activity as an actionable outcome in practice. J. Neurol. Sci. 2017, 383, 31–34. [Google Scholar] [CrossRef]
- Havrdova, E.; Galetta, S.; Hutchinson, M.; Stefoski, D.; Bates, D.; Polman, C.H.; O’Connor, P.W.; Giovannoni, G.; Phillips, J.T.; Lublin, F.D.; et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009, 8, 254–260. [Google Scholar] [CrossRef]
- Kaufmann, M.; Schaupp, A.L.; Sun, R.; Coscia, F.; Dendrou, C.A.; Cortes, A.; Kaur, G.; Evans, H.G.; Mollbrink, A.; Navarro, J.F.; et al. Identification of early neurodegenerative pathways in progressive multiple sclerosis. Nat. Neurosci. 2022, 25, 944–955. [Google Scholar] [CrossRef]
- Matsushita, T.; Tateishi, T.; Isobe, N.; Yonekawa, T.; Yamasaki, R.; Matsuse, D.; Murai, H.; Kira, J.I. Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis. PLoS ONE 2013, 8, e61835. [Google Scholar] [CrossRef] [PubMed]
- Stampanoni Bassi, M.; Iezzi, E.; Drulovic, J.; Pekmezovic, T.; Gilio, L.; Furlan, R.; Finardi, A.; Marfia, G.A.; Sica, F.; Centonze, D.; et al. IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple Sclerosis. Front. Cell. Neurosci. 2020, 14, 120. [Google Scholar] [CrossRef]
- Gilio, L.; Buttari, F.; Pavone, L.; Iezzi, E.; Galifi, G.; Dolcetti, E.; Azzolini, F.; Bruno, A.; Borrelli, A.; Storto, M.; et al. Fatigue in Multiple Sclerosis Is Associated with Reduced Expression of Interleukin-10 and Worse Prospective Disease Activity. Biomedicines 2022, 10, 2058. [Google Scholar] [CrossRef]
- Olsson, T.; Barcellos, L.F.; Alfredsson, L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat. Rev. Neurol. 2017, 13, 25–36. [Google Scholar] [CrossRef] [PubMed]
- Polman, C.H.; Reingold, S.C.; Edan, G.; Filippi, M.; Hartung, H.P.; Kappos, L.; Lublin, F.D.; Metz, L.M.; McFarland, H.F.; O’Connor, P.W.; et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann. Neurol. 2005, 58, 840–846. [Google Scholar] [CrossRef] [PubMed]
- Giovannoni, G.; Tomic, D.; Bright, J.R.; Havrdová, E. ‘No evident disease activity’: The use of combined assessments in the management of patients with multiple sclerosis. Mult. Scler. J. 2017, 23, 1179–1187. [Google Scholar] [CrossRef] [PubMed]
N (230) | RR-MS (157) | P-MS (38) | IC (35) |
---|---|---|---|
Age at LP (Median, IQR) | 33.9 (25.7–44.0) | 50.3 (45.6–56.8) | 41.8 (32.3–49.7) |
Sex, F/M (N, %) | 108/49 (68.8) | 19/38 (50) | 23/12 (65.7) |
Disease duration, months (Median, IQR) | 5 (1.1–24.3) | 24.6 (11.8–72.6) | - |
Radiological activity (yes = 1, no = 0) (N/tot, %) | 66/153 (43.1) * | 10/34 (29.4) * | - |
OCBs (yes = 1, no = 0) (N/tot, %) | 120/154 (77.9) * | 31/37 (83.8) * | - |
EDSS at LP (Median, IQR) | 2 (1.0–2.5) | 3.5 (2.5–5.5) | - |
EDSS at first year after LP (Median, IQR) | 1 (1.0–2.0) * | 5 (3.5–6.0) * | - |
EDSS at second year after LP (Median, IQR) | 1 (1.0–2.0) * | 5.5 (3.5–6.0) * | - |
NEDA-3 (yes = 1, no = 0) (N/tot, %) | 54/142 (40.0) * | - | - |
N (195) | CT/TT Allele (115) | CC Allele (80) | p |
---|---|---|---|
Age at LP (Median, IQR) | 38.8 (28.7–48.3) | 36.2 (25.4–51.6) | 0.604 |
Sex, F/M (N, %) | 77/38 (67.0) | 50/30 (62.5) | 0.312 |
OCBs (yes = 1, no = 0) (N/tot, %) | 93/115 (83) * | 58/79 (73.4) | 0.077 |
Disease duration, months (Median, IQR) | 11.6 (1.3–33.8) | 6.0 (1.7–36.0) | 0.661 |
Radiological activity (yes = 1, no = 0) (N/tot, %) | 43/109 (39.4) * | 33/78 (42.3) * | 0.404 |
EDSS at LP (Median, IQR) | 2 (1.0–3.0) | 2 (1–2.5) | 0.214 |
EDSS at first year after LP (Median, IQR) | 2 (1.0–3.0) * | 1.5 (1–2) * | 0.149 |
EDSS at second year after LP (Median, IQR) | 2 (1.0–3.5) * | 1 (1–2.5) * | 0.120 |
NEDA-3 (yes = 1, no = 0) (N/tot, %) | 24/81 (29.6) * | 30/61 (49.2) * | 0.023 |
B | S.E. | p | 95% C.I. | Exp (B) | |
---|---|---|---|---|---|
IL-5 rs2069812 groups (CT/TT, CC) | 1.146 | 0.426 | 0.007 | 1.364–7.248 | 3.144 |
Sex (F = 1, M = 0) | 0.408 | 0.455 | 0.370 | 0.616–3.668 | 1.503 |
Age | 0.016 | 0.018 | 0.376 | 0.981–1.052 | 1.016 |
EDSS at LP | 0.034 | 0.206 | 0.869 | 0.691–1.549 | 1.035 |
OCBs (1 = yes, 0 = no) | 1.480 | 0.690 | 0.053 | 1.148–16.673 | 4.375 |
DMTs (high efficacy = 1, low efficacy = 0) | 0.598 | 0.519 | 0.249 | 0.658–5.029 | 1.234 |
(Constant) | −3.463 | 1.093 | 0.002 | 0.031 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dolcetti, E.; Buttari, F.; Bruno, A.; Azzolini, F.; Gilio, L.; Borrelli, A.; Di Caprio, V.; Lauritano, G.; Galifi, G.; Gambardella, S.; et al. An IL-5 Single-Nucleotide Polymorphism Influences Neuroinflammation and Prospective Disease Activity in Multiple Sclerosis. Int. J. Mol. Sci. 2024, 25, 9108. https://doi.org/10.3390/ijms25169108
Dolcetti E, Buttari F, Bruno A, Azzolini F, Gilio L, Borrelli A, Di Caprio V, Lauritano G, Galifi G, Gambardella S, et al. An IL-5 Single-Nucleotide Polymorphism Influences Neuroinflammation and Prospective Disease Activity in Multiple Sclerosis. International Journal of Molecular Sciences. 2024; 25(16):9108. https://doi.org/10.3390/ijms25169108
Chicago/Turabian StyleDolcetti, Ettore, Fabio Buttari, Antonio Bruno, Federica Azzolini, Luana Gilio, Angela Borrelli, Veronica Di Caprio, Gianluca Lauritano, Giovanni Galifi, Stefano Gambardella, and et al. 2024. "An IL-5 Single-Nucleotide Polymorphism Influences Neuroinflammation and Prospective Disease Activity in Multiple Sclerosis" International Journal of Molecular Sciences 25, no. 16: 9108. https://doi.org/10.3390/ijms25169108